sábado, 13 de noviembre de 2021

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab - The Lancet Rheumatology

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab - The Lancet Rheumatology

No hay comentarios:

Publicar un comentario